Cargando…
The Lysine Methylase SMYD3 Modulates Mesendodermal Commitment during Development
SMYD3 (SET and MYND domain containing protein 3) is a methylase over-expressed in cancer cells and involved in oncogenesis. While several studies uncovered key functions for SMYD3 in cancer models, the SMYD3 role in physiological conditions has not been fully elucidated yet. Here, we dissect the rol...
Autores principales: | Fittipaldi, Raffaella, Floris, Pamela, Proserpio, Valentina, Cotelli, Franco, Beltrame, Monica, Caretti, Giuseppina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157265/ https://www.ncbi.nlm.nih.gov/pubmed/34069776 http://dx.doi.org/10.3390/cells10051233 |
Ejemplares similares
-
SMYD3 promotes the epithelial–mesenchymal transition in breast cancer
por: Fenizia, Claudio, et al.
Publicado: (2019) -
SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways
por: Bottino, Cinzia, et al.
Publicado: (2020) -
Tackling Skeletal Muscle Cells Epigenome in the Next-Generation Sequencing Era
por: Fittipaldi, Raffaella, et al.
Publicado: (2012) -
Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN()()
por: Nakakido, Makoto, et al.
Publicado: (2015) -
Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase
por: Talibov, Vladimir O., et al.
Publicado: (2021)